Abstract
Historically, mammalian caspases (a group of cysteine proteases) have been catalogued into two main families based on major biological function: inflammatory caspases and apoptotic caspases. Accumulating evidence from preclinical models, however, argues against such a clearcut distinction, for two main reasons. First, at least in mammals, apoptotic caspases are generally dispensable for cells to succumb to apoptotic stimuli but instead regulate the kinetic and microenvironmental manifestations of the cellular demise in the context of a complex interplay with other cell death pathways. Second, most (if not all) mammalian caspases have evolved into positive or negative regulators of inflammatory processes, either directly or via their ability to control apoptotic and non-apoptotic cell death modalities. Here we discuss the molecular mechanisms through which mammalian caspases regulate inflammation, with emphasis on the ability of apoptotic caspases to suppress inflammatory responses in support of preserved organismal homeostasis.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout



Similar content being viewed by others
References
Eckhart, L. et al. Identification of novel mammalian caspases reveals an important role of gene loss in shaping the human caspase repertoire. Mol. Biol. Evol. 25, 831–841 (2008).
Ross, C. et al. Inflammatory caspases: toward a unified model for caspase activation by inflammasomes. Annu. Rev. Immunol. 40, 249–269 (2022).
Vitale, I. et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 30, 1097–1154 (2023).
Green, D. R. Caspases and their substrates. Cold Spring Harb. Perspect. Biol. 14, a041012 (2022).
Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat. Rev. Immunol. 20, 143–157 (2020).
Galluzzi, L., López-Soto, A., Kumar, S. & Kroemer, G. Caspases connect cell-death signaling to organismal homeostasis. Immunity 44, 221–231 (2016).
Avery, L. & Horvitz, H. R. A cell that dies during wild-type C. elegans development can function as a neuron in a CED-3 mutant. Cell 51, 1071–1078 (1987). To our knowledge, this study is the first demonstration that the nematode homologue of caspase 3 is strictly required for programmed cell death during neuronal development.
Quinn, L. M. et al. An essential role for the caspase dronc in developmentally programmed cell death in Drosophila. J. Biol. Chem. 275, 40416–40424 (2000).
Daish, T. J., Mills, K. & Kumar, S. Drosophila caspase DRONC is required for specific developmental cell death pathways and stress-induced apoptosis. Dev. Cell 7, 909–915 (2004).
Galluzzi, L. et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22, 58–73 (2015).
Chipuk, J. E. & Green, D. R. Do inducers of apoptosis trigger caspase-independent cell death? Nat. Rev. Mol. Cell Biol. 6, 268–275 (2005).
Kuida, K. et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384, 368–372 (1996).
Fernando, P., Brunette, S. & Megeney, L. A. Neural stem cell differentiation is dependent upon endogenous caspase 3 activity. FASEB J. 19, 1671–1673 (2005).
Williams, D. W., Kondo, S., Krzyzanowska, A., Hiromi, Y. & Truman, J. W. Local caspase activity directs engulfment of dendrites during pruning. Nat. Neurosci. 9, 1234–1236 (2006).
Kuida, K. et al. Reduced apoptosis and cytochrome C-mediated caspase activation in mice lacking caspase 9. Cell 94, 325–337 (1998).
Yoshida, H. et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94, 739–750 (1998).
Lakhani, S. A. et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311, 847–851 (2006).
Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21, 678–695 (2020).
Lartigue, L. et al. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol. Biol. Cell 20, 4871–4884 (2009).
Vandenabeele, P., Bultynck, G. & Savvides, S. N. Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nat. Rev. Mol. Cell Biol. 24, 312–333 (2023).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015). These authors elegantly provided a mechanistic connection between inflammasome signalling and regulated cell death via pyroptosis.
Kayagaki, N. et al. NINJ1 mediates plasma membrane rupture during lytic cell death. Nature 591, 131–136 (2021).
Kayagaki, N. et al. Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury. Nature 618, 1072–1077 (2023).
Pourmal, S. et al. Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture. Nature 637, 446–452 (2025).
Chen, K. W. et al. Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. Sci. Immunol. 3, eaar6676 (2018).
Thiam, H. R., Wong, S. L., Wagner, D. D. & Waterman, C. M. Cellular mechanisms of NETosis. Annu. Rev. Cell Dev. Biol. 36, 191–218 (2020).
Kostura, M. J. et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc. Natl Acad. Sci. USA 86, 5227–5231 (1989).
Ghayur, T. et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 386, 619–623 (1997).
Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417–426 (2002).
Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).
Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Kanneganti, T. D. et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233–236 (2006).
Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213–218 (2004).
Srinivasula, S. M. et al. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277, 21119–21122 (2002).
Wang, S. et al. Identification and characterization of Ich-3, a member of the interleukin-1beta converting enzyme (ICE)/CED-3 family and an upstream regulator of ICE. J. Biol. Chem. 271, 20580–20587 (1996).
Wang, S. et al. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 92, 501–509 (1998).
Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117–121 (2011). This article demonstrated that caspase 11 is critical for optimal inflammatory outputs in response to infection by Gram-negative bacteria.
Rathinam, V. A. et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 150, 606–619 (2012).
Sollberger, G., Strittmatter, G. E., Kistowska, M., French, L. E. & Beer, H. D. Caspase-4 is required for activation of inflammasomes. J. Immunol. 188, 1992–2000 (2012).
Baker, P. J. et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur. J. Immunol. 45, 2918–2926 (2015).
Viganò, E. et al. Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes. Nat. Commun. 6, 8761 (2015).
Devant, P. et al. Structural insights into cytokine cleavage by inflammatory caspase-4. Nature 624, 451–459 (2023).
Exconde, P. M. et al. The tetrapeptide sequence of IL-18 and IL-1β regulates their recruitment and activation by inflammatory caspases. Cell Rep. 42, 113581 (2023).
Shi, X. et al. Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome. Nature 624, 442–450 (2023).
Moretti, J. et al. Caspase-11 interaction with NLRP3 potentiates the noncanonical activation of the NLRP3 inflammasome. Nat. Immunol. 23, 705–717 (2022).
Huang, J. et al. The human disease-associated gene ZNFX1 controls inflammation through inhibition of the NLRP3 inflammasome. EMBO J. 43, 5469–5493 (2024).
Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).
Vanaja, S. K. et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell 165, 1106–1119 (2016).
Zanoni, I. et al. An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 352, 1232–1236 (2016).
Santos, J. C. et al. Human GBP1 binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria. Nat. Commun. 11, 3276 (2020).
Wandel, M. P. et al. Guanylate-binding proteins convert cytosolic bacteria into caspase-4 signaling platforms. Nat. Immunol. 21, 880–891 (2020).
Wang, X. et al. SNX10-mediated LPS sensing causes intestinal barrier dysfunction via a caspase-5-dependent signaling cascade. EMBO J. 40, e108080 (2021).
Enosi Tuipulotu, D. et al. Immunity against Moraxella catarrhalis requires guanylate-binding proteins and caspase-11-NLRP3 inflammasomes. EMBO J. 42, e112558 (2023).
Man, S. M. et al. IRGB10 liberates bacterial ligands for sensing by the AIM2 and caspase-11–NLRP3 inflammasomes. Cell 167, 382–396.e317 (2016).
Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514–518 (2009).
Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J. & Alnemri, E. S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509–513 (2009).
Tenthorey, J. L. et al. The structural basis of flagellin detection by NAIP5: a strategy to limit pathogen immune evasion. Science 358, 888–893 (2017).
Sansonetti, P. J. et al. Caspase-1 activation of IL-1β and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 12, 581–590 (2000).
Lara-Tejero, M. et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407–1412 (2006).
Broz, P. et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490, 288–291 (2012).
Fattinger, S. A. et al. Gasdermin D is the only gasdermin that provides protection against acute Salmonella gut infection in mice. Proc. Natl Acad. Sci. USA 120, e2315503120 (2023).
Mariathasan, S., Weiss, D. S., Dixit, V. M. & Monack, D. M. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J. Exp. Med. 202, 1043–1049 (2005).
Kovacs, S. B. et al. Neutrophil caspase-11 is essential to defend against a cytosol-invasive bacterium. Cell Rep. 32, 107967 (2020).
Batista, S. J. et al. Gasdermin-D-dependent IL-1α release from microglia promotes protective immunity during chronic Toxoplasma gondii infection. Nat. Commun. 11, 3687 (2020).
Thomas, P. G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566–575 (2009).
Lee, S. et al. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature 597, 415–419 (2021).
Zhu, S. et al. Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells. Nature 546, 667–670 (2017).
Aachoui, Y. et al. Caspase-11 protects against bacteria that escape the vacuole. Science 339, 975–978 (2013).
Li, Z. et al. Shigella evades pyroptosis by arginine ADP-riboxanation of caspase-11. Nature 599, 290–295 (2021). These authors reported a novel mechanism through which some pathogens evade inflammasome activation by disabling caspase 11 activity.
Han, C. et al. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci. Immunol. 6, eabc6998 (2021).
Amali, A. A. et al. Extracorporeal membrane oxygenation-dependent fulminant melioidosis from caspase 4 mutation reversed by interferon gamma therapy. Clin. Infect. Dis. 78, 94–97 (2024).
Flores, J. et al. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nat. Commun. 9, 3916 (2018).
Kerur, N. et al. cGAS drives noncanonical-inflammasome activation in age-related macular degeneration. Nat. Med. 24, 50–61 (2018).
Hisahara, S., Yuan, J., Momoi, T., Okano, H. & Miura, M. Caspase-11 mediates oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination. J. Exp. Med. 193, 111–122 (2001).
Li, P. et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80, 401–411 (1995).
Cheng, K. T. et al. Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury. J. Clin. Invest. 127, 4124–4135 (2017).
Hagar, J. A., Powell, D. A., Aachoui, Y., Ernst, R. K. & Miao, E. A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341, 1250–1253 (2013).
Han, J. H. et al. NINJ1 mediates inflammatory cell death, PANoptosis, and lethality during infection conditions and heat stress. Nat. Commun. 15, 1739 (2024).
Lee, B. L. et al. Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation. J. Exp. Med. 215, 2279–2288 (2018).
Lamkanfi, M. et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185, 4385–4392 (2010).
Wei, C. et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature 629, 893–900 (2024).
Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl Acad. Sci. USA 107, 21635–21640 (2010).
Błażejewski, A. J. et al. Microbiota normalization reveals that canonical caspase-1 activation exacerbates chemically induced intestinal inflammation. Cell Rep. 19, 2319–2330 (2017).
Xu, W. et al. Apaf-1 pyroptosome senses mitochondrial permeability transition. Cell Metab. 33, 424–436 e410 (2021).
Malik, A. F. et al. Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response. Proc. Natl Acad. Sci. USA 108, 20095–20100 (2011).
Stienstra, R. et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593–605 (2010).
Zasłona, Z. et al. Caspase-11 promotes allergic airway inflammation. Nat. Commun. 11, 1055 (2020).
Lu, Y. et al. Caspase-11 signaling enhances graft-versus-host disease. Nat. Commun. 10, 4044 (2019).
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
Eltobgy, M. M. et al. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc. Natl Acad. Sci. USA 119, e2202012119 (2022).
Flores, J., Noël, A., Foveau, B., Beauchet, O. & LeBlanc, A. C. Pre-symptomatic caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat. Commun. 11, 4571 (2020).
Melnikov, V. Y. et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J. Clin. Invest. 110, 1083–1091 (2002).
Kajiwara, Y. et al. A critical role for human caspase-4 in endotoxin sensitivity. J. Immunol. 193, 335–343 (2014).
Jones, J. W. et al. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc. Natl Acad. Sci. USA 107, 9771–9776 (2010).
Sutterwala, F. S. et al. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J. Exp. Med. 204, 3235–3245 (2007).
Lee, E. et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 26, 213–228 (2019).
Reinke, S. et al. Non-canonical caspase-1 signaling drives RIP2-dependent and TNF-α-mediated inflammation in vivo. Cell Rep. 30, 2501–2511.e2505 (2020).
Monteleone, M. et al. Interleukin-1β maturation triggers its relocation to the plasma membrane for Gasdermin-D-dependent and -independent secretion. Cell Rep. 24, 1425–1433 (2018).
Schneider, K. S. et al. The inflammasome drives GSDMD-independent secondary pyroptosis and IL-1 release in the absence of caspase-1 protease activity. Cell Rep. 21, 3846–3859 (2017).
Gutierrez, K. D. et al. MLKL activation triggers NLRP3-mediated processing and release of IL-1β independently of Gasdermin-D. J. Immunol. 198, 2156–2164 (2017).
Du, G. et al. ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D. Nature 630, 437–446 (2024).
Wright, S. S. et al. Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells. Cell 188, 280–291.e217 (2025).
Galluzzi, L. & Green, D. R. Autophagy-independent functions of the autophagy machinery. Cell 177, 1682–1699 (2019).
Dupont, N. et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J. 30, 4701–4711 (2011). This manuscript showed that, at least in some settings, IL-1β secretion involves non-canonical activities of the autophagy apparatus.
Py, B. F. et al. Caspase-11 controls interleukin-1β release through degradation of TRPC1. Cell Rep. 6, 1122–1128 (2014).
Aizawa, E. et al. GSDME-dependent incomplete pyroptosis permits selective IL-1α release under caspase-1 inhibition. iScience 23, 101070 (2020).
Xia, S. et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature 593, 607–611 (2021).
Hu, Y. et al. The Gasdermin D N-terminal fragment acts as a negative feedback system to inhibit inflammasome-mediated activation of caspase-1/11. Proc. Natl Acad. Sci. USA 119, e2210809119 (2022).
Miao, R. et al. Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity 56, 2523–2541 e2528 (2023).
Tang, Y. et al. Cardiolipin oxidized by ROS from complex II acts as a target of gasdermin D to drive mitochondrial pore and heart dysfunction in endotoxemia. Cell Rep. 43, 114237 (2024).
Heilig, R. et al. Caspase-1 cleaves Bid to release mitochondrial SMAC and drive secondary necrosis in the absence of GSDMD. Life Sci. Alliance 3, e202000735 (2020).
Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666–671 (2015).
Li, S. et al. Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis. J. Exp. Med. 216, 2562–2581 (2019).
Humphries, F. et al. Succination inactivates gasdermin D and blocks pyroptosis. Science 369, 1633–1637 (2020).
Bulek, K. et al. Epithelial-derived gasdermin D mediates nonlytic IL-1β release during experimental colitis. J. Clin. Invest. 130, 4218–4234 (2020).
Liu, Y. et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 5, eaax7969 (2020).
Berghe, T. V. et al. Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. Am. J. Respir. Crit. Care Med. 189, 282–291 (2014).
Brydges, S. D. et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J. Clin. Invest. 123, 4695–4705 (2013).
Rühl, S. et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science 362, 956–960 (2018).
Li, Z. et al. Enhancing gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nat. Commun. 13, 6321 (2022).
Gong, Y. N. et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 169, 286–300 e216 (2017).
Yoon, S., Kovalenko, A., Bogdanov, K. & Wallach, D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47, 51–65 e57 (2017).
Wang, W. et al. Sensing plasma membrane pore formation induces chemokine production in survivors of regulated necrosis. Dev. Cell 57, 228–245 e226 (2022).
Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817–827 (1996).
Chinnaiyan, A. M. et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990–992 (1996).
Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G. & Alnemri, E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple CED-3/ICE-like cysteine proteases. Proc. Natl Acad. Sci. USA 93, 14486–14491 (1996).
Chun, H. J. et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419, 395–399 (2002).
Weng, D. et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc. Natl Acad. Sci. USA 111, 7391–7396 (2014).
Philip, N. H. et al. Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling. Proc. Natl Acad. Sci. USA 111, 7385–7390 (2014).
Gaidt, M. M. et al. Human monocytes engage an alternative inflammasome pathway. Immunity 44, 833–846 (2016).
Vince, J. E. et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36, 215–227 (2012).
Bossaller, L. et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol. 189, 5508–5512 (2012).
Vince, J. E. et al. The mitochondrial apoptotic effectors BAX/BAK activate caspase-3 and -7 to trigger NLRP3 inflammasome and caspase-8 driven IL-1β activation. Cell Rep. 25, 2339–2353.e2334 (2018).
Donado, C. A. et al. A two-cell model for IL-1β release mediated by death-receptor signaling. Cell Rep. 31, 107466 (2020).
Maelfait, J. et al. Stimulation of toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J. Exp. Med. 205, 1967–1973 (2008).
Kang, S. et al. Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3. Nat. Commun. 6, 7515 (2015). These authors elegantly demonstrated that caspase 8 can drive inflammasome activation upon TLR signalling, irrespective of proteolytic activity.
DeLaney, A. A. et al. Caspase-8 promotes c-Rel-dependent inflammatory cytokine expression and resistance against Toxoplasma gondii. Proc. Natl Acad. Sci. USA 116, 11926–11935 (2019).
Henry, C. M. & Martin, S. J. Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory “FADDosome” complex upon TRAIL stimulation. Mol. Cell 65, 715–729 e715 (2017).
Allam, R. et al. Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming. EMBO Rep. 15, 982–990 (2014).
Orning, P. et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science 362, 1064–1069 (2018).
Jena, K. K. et al. Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair. Cell 187, 7533–7550.e7523 (2024).
Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. Embo J. 28, 578–590 (2009).
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G. & Marincola, F. M. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug. Discov. 23, 445–460 (2024). This is a comprehensive review on the molecular mechanisms and therapeutic implications of immunogenic cell death in cancer and infectious diseases.
Gitlin, A. D. et al. Integration of innate immune signalling by caspase-8 cleavage of N4BP1. Nature 587, 275–280 (2020).
Takahashi, K. et al. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J. Immunol. 176, 4520–4524 (2006).
Wachter, T. et al. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kB activation at the death-inducing signaling complex in human keratinocytes. J. Biol. Chem. 279, 52824–52834 (2004).
Aaes, T. L. et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15, 274–287 (2016).
Yatim, N. et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. Science 350, 328–334 (2015).
Orozco, S. L. et al. RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. Cell Rep. 28, 2275–2287.e2275 (2019).
Oberst, A. et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature 471, 363–367 (2011). These authors documented the ability of caspase 8–cFLIPL heterodimers to suppress necroptosis through their catalytic activity.
Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368–372 (2011). This article demonstrated that the embryonically lethal phenotype imposed by the whole-body deletion of Casp8 can be fully rescued by the co-deletion of Ripk3.
Alvarez-Diaz, S. et al. The pseudokinase MLKL and the kinase RIPK3 have distinct roles in autoimmune disease caused by loss of death-receptor-induced apoptosis. Immunity 45, 513–526 (2016).
Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).
Weinlich, R. et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep. 5, 340–348 (2013).
Newton, K. et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature 574, 428–431 (2019).
O’Donnell, M. A. et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13, 1437–1442 (2011).
Tran, H. T. et al. RIPK3 cleavage is dispensable for necroptosis inhibition but restricts NLRP3 inflammasome activation. Cell Death Differ. 31, 662–671 (2024).
Newton, K. et al. Activity of caspase-8 determines plasticity between cell death pathways. Nature 575, 679–682 (2019).
Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683–687 (2019). Together with ref. 159, these two manuscripts elegantly demonstrated that caspase 8 operates as an apical switch between different cell death modalities.
Tummers, B. et al. Caspase-8-dependent inflammatory responses are controlled by its adaptor, FADD, and necroptosis. Immunity 52, 994–1006.e1008 (2020).
Wang, Y. et al. Molecular mechanism of RIPK1 and caspase-8 in homeostatic type I interferon production and regulation. Cell Rep. 41, 111434 (2022).
Kang, T. B., Yang, S. H., Toth, B., Kovalenko, A. & Wallach, D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38, 27–40 (2013).
Kim, S., Lu, H. C., Steelman, A. J. & Li, J. Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1β production and CD4 T cell activation in autoimmune demyelination. Proc. Natl Acad. Sci. USA 119, e2117636119 (2022).
Teh, C. E. et al. Caspase-8 has dual roles in regulatory T cell homeostasis balancing immunity to infection and collateral inflammatory damage. Sci. Immunol. 7, eabn8041 (2022).
Tanchot, C. et al. Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 6, 147–157 (2013).
Pereira, L. M. N. et al. Caspase-8 mediates inflammation and disease in rodent malaria. Nat. Commun. 11, 4596 (2020).
Mandal, P. et al. Caspase-8 collaborates with caspase-11 to drive tissue damage and execution of endotoxic shock. Immunity 49, 42–55.e46 (2018).
Simpson, D. S. et al. Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway. Immunity 55, 423–441.e429 (2022).
Heger, K. et al. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature 559, 120–124 (2018).
Zhang, J. et al. Ubiquitin ligases cIAP1 and cIAP2 limit cell death to prevent inflammation. Cell Rep. 27, 2679–2689.e2673 (2019).
Burguillos, M. A. et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 472, 319–324 (2011).
Feng, Y. et al. Remarkably robust antiviral immune response despite combined deficiency in caspase-8 and RIPK3. J. Immunol. 201, 2244–2255 (2018).
Feng, Y. et al. Caspase-8 restricts antiviral CD8 T cell hyperaccumulation. Proc. Natl Acad. Sci. USA 116, 15170–15177 (2019).
Rickard, J. A. et al. TNFR1-dependent cell death drives inflammation in sharpin-deficient mice. eLife 3, e03464 (2014).
Günther, C. et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 477, 335–339 (2011).
Schwarzer, R., Jiao, H., Wachsmuth, L., Tresch, A. & Pasparakis, M. FADD and caspase-8 regulate gut homeostasis and inflammation by controlling MLKL- and GSDMD-mediated death of intestinal epithelial cells. Immunity 52, 978–993.e976 (2020).
Kovalenko, A. et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J. Exp. Med. 206, 2161–2177 (2009).
Dillon, C. P. et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157, 1189–1202 (2014).
Takahashi, N. et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95–99 (2014). Together with ref. 179, these authors provided robust data supporting the notion that RIPK1 functions are critical to prevent cell death and inflammation downstream of apoptosis and necroptosis.
Lalaoui, N. et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature 577, 103–108 (2020).
Tao, P. et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature 577, 109–114 (2020).
Duan, H. et al. ICE-LAP6, a novel member of the ICE/CED-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J. Biol. Chem. 271, 16720–16724 (1996).
Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489 (1997).
White, M. J. et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159, 1549–1562 (2014).
Rongvaux, A. et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell 159, 1563–1577 (2014). Together with ref. 185, these two back-to-back articles demonstrated that apoptotic caspases potently suppress type I interferon synthesis as promoted by MOMP.
Ning, X. et al. Apoptotic caspases suppress type I interferon production via the cleavage of cGAS, MAVS, and IRF3. Mol. Cell 74, 19–31 e17 (2019).
Han, C. et al. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nat. Immunol. 21, 546–554 (2020).
Giampazolias, E. et al. Mitochondrial permeabilization engages NF-kB-dependent anti-tumour activity under caspase deficiency. Nat. Cell Biol. 19, 1116–1129 (2017).
Avrutsky, M. I. et al. Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion. Nat. Commun. 11, 3173 (2020).
Rothlin, C. V., Hille, T. D. & Ghosh, S. Determining the effector response to cell death. Nat. Rev. Immunol. 21, 292–304 (2021).
Fernandes-Alnemri, T., Litwack, G. & Alnemri, E. S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein CED-3 and mammalian interleukin-1 β-converting enzyme. J. Biol. Chem. 269, 30761–30764 (1994).
Tewari, M. et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801–809 (1995).
Nicholson, D. W. et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37–43 (1995).
Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175–193 (2019).
Vanpouille-Box, C., Hoffmann, J. A. & Galluzzi, L. Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles. Nat. Rev. Drug. Discov. 18, 845–867 (2019).
Rodriguez-Ruiz, M. E. et al. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology 8, e1655964 (2019).
Killarney, S. T. et al. Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis. Nat. Commun. 14, 1399 (2023).
Suzuki, J., Denning, D. P., Imanishi, E., Horvitz, H. R. & Nagata, S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 341, 403–406 (2013).
Segawa, K. et al. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 344, 1164–1168 (2014).
Sukka, S. R. et al. Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution. Nat. Metab. 6, 1736–1755 (2024).
Fadok, V. A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890–898 (1998).
Hanayama, R. et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304, 1147–1150 (2004).
Fadok, V. A. et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85–90 (2000).
Huang, Q. et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 17, 860–866 (2011).
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
Lauber, K. et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113, 717–730 (2003).
De Martino, M., Rathmell, J. C., Galluzzi, L. & Vanpouille-Box, C. Cancer cell metabolism and antitumour immunity. Nat. Rev. Immunol. 24, 654–669 (2024).
Chekeni, F. B. et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. Nature 467, 863–867 (2010).
Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282–286 (2009).
Medina, C. B. et al. Metabolites released from apoptotic cells act as tissue messengers. Nature 580, 130–135 (2020).
Lüthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84–98 (2009).
Wright, S. S. et al. A bacterial toxin co-opts caspase-3 to disable active gasdermin D and limit macrophage pyroptosis. Cell Rep. 43, 114004 (2024).
He, K. et al. Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine. Cell 186, 3033–3048 e3020 (2023).
Srikanth, C. V. et al. Salmonella pathogenesis and processing of secreted effectors by caspase-3. Science 330, 390–393 (2010).
Martins, I. et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 21, 79–91 (2014).
Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729–741 (2013).
Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
Wang, Y. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 99–103 (2017). This report provided robust mechanistic data linking caspase 3 activation to GSDME-dependent pyroptosis in cancer cells.
Lu, H. et al. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin. Cancer Res. 24, 6066–6077 (2018).
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat. Commun. 10, 1689 (2019).
Sun, S. J. et al. Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS–STING activation. Nat. Commun. 15, 6640 (2024).
Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).
Buqué, A., Rodriguez-Ruiz, M. E., Fucikova, J. & Galluzzi, L. Apoptotic caspases cut down the immunogenicity of radiation. Oncoimmunology 8, e1655364 (2019).
Fernandes-Alnemri, T., Litwack, G. & Alnemri, E. S. Mch2, a new member of the apoptotic CED-3/Ice cysteine protease gene family. Cancer Res. 55, 2737–2742 (1995).
Fernandes-Alnemri, T. et al. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res. 55, 6045–6052 (1995).
Walsh, J. G. et al. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc. Natl Acad. Sci. USA 105, 12815–12819 (2008).
Berta, T. et al. Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-α secretion. J. Clin. Invest. 124, 1173–1186 (2014).
Zheng, M., Karki, R., Vogel, P. & Kanneganti, T. D. Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell 181, 674–687.e613 (2020).
Kobayashi, H. et al. Neutrophils activate alveolar macrophages by producing caspase-6-mediated cleavage of IL-1 receptor-associated kinase-M. J. Immunol. 186, 403–410 (2011).
Graham, R. K. et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125, 1179–1191 (2006).
Horowitz, P. M. et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer’s disease. J. Neurosci. 24, 7895–7902 (2004).
Nozaki, K. et al. Caspase-7 activates ASM to repair gasdermin and perforin pores. Nature 606, 960–967 (2022). These authors identified a caspase 7-dependent mechanism that suppresses pyroptosis by favoring the repair of GSDMD pores.
Erener, S. et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes. Mol. Cell 46, 200–211 (2012).
Lamkanfi, M. et al. Caspase-7 deficiency protects from endotoxin-induced lymphocyte apoptosis and improves survival. Blood 113, 2742–2745 (2009).
Kumar, S., Kinoshita, M., Noda, M., Copeland, N. G. & Jenkins, N. A. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the caenorhabditis elegans cell death gene CED-3 and the mammalian IL-1 beta-converting enzyme. Genes. Dev. 8, 1613–1626 (1994).
Tinel, A. & Tschopp, J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304, 843–846 (2004).
Upton, J. P. et al. Caspase-2 cleavage of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress. Mol. Cell Biol. 28, 3943–3951 (2008).
Li, X. & He, Y. Caspase-2-dependent dendritic cell death, maturation, and priming of T cells in response to Brucella abortus infection. PLoS ONE 7, e43512 (2012).
Bronner, D. N. et al. Endoplasmic reticulum stress activates the inflammasome via NLRP3- and caspase-2-driven mitochondrial damage. Immunity 43, 451–462 (2015).
Fernandes-Alnemri, T. et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc. Natl Acad. Sci. USA 93, 7464–7469 (1996).
Wang, J. et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98, 47–58 (1999).
Sprick, M. R. et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21, 4520–4530 (2002).
Cho, M. et al. Caspase-10 affects the pathogenesis of primary biliary cholangitis by regulating inflammatory cell death. J. Autoimmun. 133, 102940 (2022).
Horn, S. et al. Caspase-10 negatively regulates caspase-8-mediated cell death, switching the response to CD95L in favor of NF-kB activation and cell survival. Cell Rep. 19, 785–797 (2017).
Roy, S. et al. Confinement of caspase-12 proteolytic activity to autoprocessing. Proc. Natl Acad. Sci. USA 105, 4133–4138 (2008).
Zong, W. X. et al. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J. Cell Biol. 162, 59–69 (2003).
Saleh, M. et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440, 1064–1068 (2006).
Saleh, M. et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429, 75–79 (2004).
Yeretssian, G. et al. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc. Natl Acad. Sci. USA 106, 9016–9020 (2009).
Wang, P. et al. Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nat. Immunol. 11, 912–919 (2010).
Vande Walle, L. et al. Does caspase-12 suppress inflammasome activation? Nature 534, E1–E4 (2016).
Hu, S., Snipas, S. J., Vincenz, C., Salvesen, G. & Dixit, V. M. Caspase-14 is a novel developmentally regulated protease. J. Biol. Chem. 273, 29648–29653 (1998).
Van de Craen, M. et al. Identification of a new caspase homologue: caspase-14. Cell Death Differ. 5, 838–846 (1998).
Eckhart, L. et al. Terminal differentiation of human keratinocytes and stratum corneum formation is associated with caspase-14 activation. J. Invest. Dermatol. 115, 1148–1151 (2000).
Lippens, S. et al. Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell Death Differ. 7, 1218–1224 (2000).
Walsh, D. S. et al. Psoriasis is characterized by altered epidermal expression of caspase 14, a novel regulator of keratinocyte terminal differentiation and barrier formation. J. Dermatol. Sci. 37, 61–63 (2005).
Denecker, G. et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat. Cell Biol. 9, 666–674 (2007).
Devos, M. et al. Filaggrin degradation by caspase-14 is required for UVB photoprotection but does not influence allergic sensitization in a mouse model of atopic dermatitis. J. Invest. Dermatol. 132, 2857–2860 (2012).
Kubica, M. et al. The skin microbiome of caspase-14-deficient mice shows mild dysbiosis. Exp. Dermatol. 23, 561–567 (2014).
Mukherjee, A. & Williams, D. W. More alive than dead: non-apoptotic roles for caspases in neuronal development, plasticity and disease. Cell Death Differ. 24, 1411–1421 (2017).
Linton, S. D. et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J. Med. Chem. 48, 6779–6782 (2005).
Wang, P. X. et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat. Med. 23, 439–449 (2017).
Gautheron, J. et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 6, 1062–1074 (2014).
Dhani, S., Zhao, Y. & Zhivotovsky, B. A long way to go: caspase inhibitors in clinical use. Cell Death Dis. 12, 949 (2021).
Gautam, A. et al. Necroptosis blockade prevents lung injury in severe influenza. Nature 628, 835–843 (2024).
Yuan, J. & Ofengeim, D. A guide to cell death pathways. Nat. Rev. Mol. Cell Biol. 25, 379–395 (2024).
Czabotar, P. E. & Garcia-Saez, A. J. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat. Rev. Mol. Cell Biol. 24, 732–748 (2023).
Bonora, M., Giorgi, C. & Pinton, P. Molecular mechanisms and consequences of mitochondrial permeability transition. Nat. Rev. Mol. Cell Biol. 23, 266–285 (2022).
Acknowledgements
K.A.S., D.R.G. and L.G. are grateful to the William Guy Forbeck Research Foundation for fostering the dissemination of knowledge, promoting scientific collaboration and supporting the training of the next generation of leaders in cancer research. D.R.G. acknowledges the support (as a PI unless otherwise indicated) of two R01 grants from the NIH/NCI (nos. CA231620 and AI44828). Among other sources, L.G. acknowledges the support (as a PI unless otherwise indicated) of one R01 grant from the NIH/NCI (no. CA271915); two Breakthrough Level 2 grants from the US DoD BCRP (nos. BC180476P1 and BC210945); a grant from the STARR Cancer Consortium (no. I16-0064); a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (no. W81XWH2120034, PI: Formenti); a U54 grant from NIH/NCI (no. CA274291, PI: Deasy, Formenti, Weichselbaum); the 2019 Laura Ziskin Prize in Translational Research (no. ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C); a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukaemia and Lymphoma Society; a Rapid Response Grant from the Functional Genomics Initiative (New York, USA); a pre-SPORE grant (PI: Demaria, Formenti); a Collaborative Research Initiative Grant and a Clinical Trials Innovation Grant from the Sandra and Edward Meyer Cancer Center (New York, USA); as well as startup funds from the Department of Radiation Oncology at Weill Cornell Medicine (New York, USA) and Fox Chase Cancer Center (Philadelphia, PA).
Author information
Authors and Affiliations
Contributions
L.G., M.B.-V. and R.S.-A. researched data for the article. All authors contributed substantially to discussion of the content. L.G., M.B.-V. and R.S.-A. wrote the article. All authors reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
D.R.G. is/has been holding research contracts with Amgen and has received consulting/advisory honoraria for Sonata Pharmaceuticals, Ventus Pharmaceuticals and ASHA Therapeutics. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, AbbVie and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. The other authors have no conflicts of interest to declare.
Peer review
Peer review information
Nature Reviews Molecular Cell Biology thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- ADP-riboxanation
-
A complex post-translational modification that involves Arg residues and can affect protein functionality.
- Antigen-presenting cells
-
Myeloid or lymphoid cells that are capable of engulfing and processing antigenic material for presentation to T lymphocytes.
- Apoptosome
-
An APAF1-dependent multiprotein complex that enables the activation of caspase 9 in response to mitochondrial outer membrane permeabilization.
- Autoimmune lymphoproliferative syndrome
-
A rare genetic disorder characterized by lymphoproliferation, autoimmune disease and an increased propensity to develop certain tumours.
- Autophagic machinery
-
The molecular machinery responsible for a lysosome-dependent catabolic pathway that disposes of superfluous, exogenous or potentially toxic cytosolic entities, including invading pathogens and permeabilized mitochondria.
- Canonical inflammasomes
-
Cytosolic multiprotein complex that enable the activation of caspase 1 and the consequent release of mature IL-1β and IL-18, coupled with GSDMD-dependent pyroptosis in response to various inflammatory cues.
- Cornified epithelium
-
The outermost layer of the skin and other stratified epithelia that forms through the death and keratinization of epithelial cells.
- Damage-associated molecular patterns
-
(DAMPs). Cell damage can cause these endogenous molecules to become exposed on the cell surface or secreted into the extracellular environment, where they interact with immune cells and mediate robust inflammatory effects.
- Dendritic cells
-
Myeloid cells that operate at the interface between innate and adaptive immune responses, by presenting antigenic material to T lymphocytes.
- Immunogenic cell death
-
A form of regulated cell death that is sufficient (in immunocompetent syngeneic hosts) to initiate adaptive immune responses targeting dead cell-associated antigens.
- Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
(MPTP). An organic compound of the tetrahydropyridine family that is commonly used to induce Parkinson disease in research animals.
- Natural killer cell
-
A lymphoid cell that mediates antigen-independent cytotoxic and secretory functions upon recognition of distress signals on infected or malignant cells.
- Necroptosis
-
A form of regulated necrosis that relies on plasma membrane permeabilization by MLKL.
- Neutrophil extracellular traps
-
(NETs). Networks of extracellular fibres containing decondensed DNA and lytic proteins that are released by dying neutrophils in response to pathogen exposure.
- Non-canonical inflammasome
-
A cytosolic multiprotein complex that enables the activation of caspase 4, caspase 5 or caspase 11 in response to intracellular LPS from Gram-negative bacteria, resulting in pyroptotic cell death and secondary activation of canonical inflammasomes.
- Phosphatidylserine
-
A phospholipid of the inner leaflet of the plasma membrane that is rapidly externalized during apoptotic cell death as a signal for efferocytosis.
- Regulatory T cells
-
Immunosuppressive T lymphocytes that are fundamental to prevent self-reactive lymphocytes in the periphery from causing autoimmunity.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Beltrán-Visiedo, M., Soler-Agesta, R., Sarosiek, K.A. et al. Regulation of inflammatory processes by caspases. Nat Rev Mol Cell Biol (2025). https://doi.org/10.1038/s41580-025-00869-6
Accepted:
Published:
DOI: https://doi.org/10.1038/s41580-025-00869-6
This article is cited by
-
The microbiota in radiotherapy-induced cancer immunosurveillance
Nature Reviews Clinical Oncology (2025)